Do you want to read an article? Please log in or register.
Longitudinal Assessment of Communication with Patient-Reported Outcomes During Lung Cancer Screening
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Tasoudis P, Loufopoulos G, Manaki V, Doerr M, Agala CB, Long JM, Haithcock BE
doi: 10.1016/j.lungcan.2024.107929
RECOMMENDED
Lung Cancer
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Barrichello APC, Elkrief A, Ricciuti B, Ganta T, Marron TU, Wang X, Lotter W, Lindsay J, Santo V, Cortellini A, Sharma B, Felt K, Pfaff K, Lamberti G, Pecci F, Federico AD, Makarem M, Gandhi MM, Nguyen T, Haradon D, Vaz VR, Johnson BE, Debnath N, Wang Y, Kuang AG, Saeed A, Radford M, Lovly CM, Nebhan CA, Pinato DJ, Rodig SJ, Schoenfeld AJ, Awad MM, Alessi JV, Naqash AR
doi: 10.1016/j.cllc.2025.01.014
Lung Cancer
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
J Clin Med
Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, Karner J, Gruber G, Stana M, Minasch D, Kirchhammer K, Steffal C, Stranzl H, Moosbrugger R, Feurstein P, Dieckmann K, Zehentmayr F, ALLSTAR Group
doi: 10.3390/jcm14030945
RECOMMENDED
Lung CancerFurther Publications
Physical activity and lung cancer screening (PALS): feasibility randomised controlled trial of exercise and physical activity in lung cancer screening
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Bonney A, Granger CL, Steinfort D, Patrick C, Marshall HM, Fong KM, Manser R
doi: 10.1186/s12931-025-03158-0
RECOMMENDED
Lung Cancer
CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Suazo-Zepeda E, Viddeleer AR, Maas WJ, Postmus D, Heuvelmans MA, Hiltermann TJN, De Bock GH
doi: 10.1016/j.lungcan.2024.108054
RECOMMENDED
Lung Cancer
The Short-Term Impact of Neoadjuvant Chemotherapy on the Outcome of Patients Undergoing Pneumonectomy for Lung Cancer: Is It Acceptable Nowadays?
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Mazzella A, Maiorca S, Nicolosi G, Maisonneuve P, Passaro A, Casiraghi M, Bertolaccini L, de Marinis F, Spaggiari L
doi: 10.3390/jcm14072419
RECOMMENDED
Lung Cancer
Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Research Consortium Study BTCRC LUN 16-081
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Wei CX, Althouse SK, Mamdani H, Hanna NH, Durm GA
doi: 10.1016/j.cllc.2024.12.007
RECOMMENDED
Lung Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
Lung Cancer
The impact of lung surgery, with or without (neo-)adjuvant therapy, on physical functioning in patients with nonsmall cell lung cancer: a scoping review
Eur Respir Rev
Haesevoets S, Arents E, Cops D, Quadflieg K, Criel M, Ruttens D, Daenen M, Stevens D, Surmont V, Demeyer H, Burtin C
doi: 10.1183/16000617.0156-2024